Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 13/20 | 0.60 |
| ▸ | CCNE1 | P24864 | 12/20 | 0.60 |
| ▸ | CDK2 | P24941 | 12/20 | 0.60 |
| ▸ | CDC7 | O00311 | 12/20 | 0.60 |
| ▸ | DBF4 | Q9UBU7 | 12/20 | 0.60 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10279661 | 0.88 | ROCK1 (0.58) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL613067 | 0.87 | CCNE1 (0.60) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL613845 | 0.86 | ROCK1 (0.61) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL612029 | 0.81 | CDC7 (0.73) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL612399 | 0.81 | CDC7 (0.61) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL611155 | 0.78 | CDC7 (0.68) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL612015 | 0.76 | CDC7 (1.00) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL614286 | 0.72 | ROCK1 (0.70) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL613466 | 0.70 | CDC7 (0.59) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL613654 | 0.69 | CDC7 (1.00) | ROCK1CCNE1CDK2CDC7DBF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691828-B2 | Thienopyrimidine as CDC7 kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-04-08 | — | — | US | disclosed |
| US-8691828-B2 | Thienopyrimidine as CDC7 kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-04-08 | — | — | US | disclosed |
| EP-2403857-B1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | CDC7, CDK7, DTYMK | ROCK1 2609/4885CCNE1 158/4885CDK2 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.